MVT-602 is an oligopeptide kisspeptin-1 receptor agonist and an investigational drug candidate for the treatment of women undergoing assisted reproduction, such as in vitro fertilization (IVF).
More than 200 study participants have received treatment with MVT-602 in Phase 1 and Phase 2 clinical trials.
MVT-602 is not approved by the FDA
Clinical Trial Results
MVT-602 is not approved by the FDA.
In October 2018, we presented data from a Phase 1 trial of MVT-602 at the American Society of Reproductive Medicine (ASRM) Scientific Congress. Results of this trial showed that administration of MVT-602 in 24 healthy premenopausal women in the follicular phase produced a dose-related increase in LH and expected post-dose increases in FSH and estrogen. Adverse events were similar between placebo and the MVT-602 groups with no apparent dose-related effects.
Recent News and Presentations
20 Aug 2019
Myovant Sciences Completes Patient Recruitment for Phase 3 SPIRIT 2 Study Evaluating Relugolix Combination Therapy in Women with Endometriosis
6 Aug 2019
Myovant Sciences Provides Recent Corporate Updates and Reports Financial Results for First Fiscal Quarter Ended June 30, 2019
23 Jul 2019
Myovant Sciences Announces Positive Results from Second Phase 3 Study Evaluating Once-Daily Relugolix Combination Therapy in Women with Uterine Fibroids and Positive Results from Bioequivalence Study